A case-control study found that patients who developed colon cancer, particularly in the proximal colon, were more likely to have taken antibiotics, whereas antibiotic use was not associated with increased risk of rectal cancer.
Data from the National Notifiable Diseases Surveillance System and the Quest Diagnostics Health Trends database were used to estimate the incidence of hepatitis C virus (HCV) infection among women ages 15 to 44 years and children ages 2 to 13 years.
An accompanying editorial said that based on the risk of gastrointestinal (GI) events found in this retrospective study, sodium polystyrene sulfonate should not be used to reduce serum potassium levels.
A retrospective trial showed no increase in new corticosteroid therapy or disease-related hospitalization or surgery among patients who discontinued 5-aminosalycilate (5-ASA) therapy when initiating an anti-tumor necrosis factor (anti-TNF) agent.
Odds of inadequate cleansing were higher in patients who were bedridden or constipated, those with diabetes, those taking antipsychotic drugs, and those hospitalized for seven days or longer.
Infliximab may have been used inappropriately in Crohn's disease and underused in ulcerative colitis, according to the authors of an analysis of hospitalizations, intestinal resections, and drug costs related to inflammatory bowel disease (IBD).
Based on the results, study authors suggested expanding colorectal cancer (CRC) screening to patients 45 years of age, but an accompanying editorial expressed concern that the risks could outweigh the benefits in the general population.
Significantly more patients taking the glucagon-like peptide-1 receptor agonist had resolution of their nonalcoholic steatohepatitis (NASH) than those taking placebo, but rates of liver fibrosis improvement were similar between groups, an
Rates of clinical remission and clinical response were 32.0% and 42.7%, respectively, in Crohn's disease patients receiving therapy with both corticosteroids and anti-tumor necrosis factor (TNF) agents and 35.5% and 46.8% in those receiving only anti
Additionally, our results highlight the potential clinical utility of echocardiography for assessing NAFLD-related HF risk.